Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Anticancer drug resistance necessitates novel therapeutic strategies.
• Natural killer (NK) and lymphokine-activated killer (LAK) cells offer potential in cancer immunotherapy.

Purpose of the Study:

• To investigate the sensitivity of multidrug-resistant (MDR) small cell lung carcinoma (SCLC) to NK and LAK cell-mediated lysis.
• To explore the role of drug resistance mechanisms, specifically P-glycoprotein (P-gp) and multidrug resistance protein (MRP), in LAK cell susceptibility.

Main Methods:

• Utilized 51Chromium release and conjugate formation assays to assess LAK cell-mediated tumor cell lysis and binding.
• Compared the sensitivity of P-gp positive (P-gp+) and MRP positive (MRP+) MDR SCLC cell lines with their drug-sensitive counterparts.

Main Results:

• P-gp+ MDR SCLC cell lines exhibited significantly greater lysis by human LAK cells compared to drug-sensitive cells.
• MRP+ MDR SCLC cell lines did not show increased susceptibility to LAK cells.
• Increased LAK cell susceptibility in P-gp+ cells was associated with a higher frequency of binding to LAK cells, not generalized target cell fragility.

Conclusions:

• P-glycoprotein expression in MDR SCLC may enhance susceptibility to LAK cell immunotherapy.
• These findings suggest a potential synergistic effect between chemotherapy and immunotherapy, particularly in P-gp expressing tumors.
• Further research may elucidate novel combination treatment strategies for SCLC.